Fujitsu and ACRES have linked up to address challenges facing the development of medicines and health-related research endeavors.
Fujitsu and ACRES have linked up to address challenges facing the development of medicines and health-related research endeavors.
Fujitsu, the Japanese information and communication technology company, and the Alliance for Clinical Research Excellence and Safety (ACRES) have linked up to address challenges facing the development of medicines and health-related research endeavors.
Fujitsu and ACRES are establishing a technical working party, the ACRES-Fujitsu Technology Innovation Group, to explore closer alignment of electronic medical records (EMRs) and clinical research information systems, which they regard as an essential step toward enabling innovative systems capabilities, including remote risk-based monitoring, online electronic auditing, and real-time pharmacovigilance safety monitoring.
The partnership is part of a larger collaborative effort, the ACRES Technology Consortium, to work out how information and communications technology can be more innovatively and effectively applied within the healthcare and health-research domains in Japan and across the ACRES Global Technology Network, in support of ACRES global system for clinical research.
“We are honored to have Fujitsu, Ltd. as our newest ally and strategic partner,” said Al Pacino, ACRES Vice-President for Collaborative Network Development. “Fujitsu’s expertise brings extraordinary resources to ACRES global technology initiatives—this is a major milestone. Successful integration of electronic health records and clinical trials information greatly furthers ACRES goal to get safe, effective medicines to the people who need them as efficiently as possible.”
Head of Fujitsu’s Next Generation Healthcare Innovation Center, Hirofumi Gouda, notes that “Fujitsu has high expectations that ACRES efforts and the Global Network System will not only greatly improve Quality Cost Delivery in the related areas in clinical trials and clinical research, but also become a very important collaborative platform for helping creating a new knowledge base, including an evolving collaboration with stakeholders in healthcare and life science worldwide.”
ACRES President and CEO, Dr. Greg Koski, added, “Emerging from the efforts of Dr. Kyoko Imamura and our colleagues at ACRES Japan, including its President, Dr Fumimaro Takaku, our partnership with Fujitsu is a landmark event. The decision of one of the world’s leading technology companies to join the ACRES Alliance attests to the power of systems thinking and multi-sector collaboration. The world of medicines development is undergoing transformation, and Fujitsu is helping ACRES Allies envision and build the future.”
Read the full release here.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.